Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP4K1 | Q92918 | 4/20 | 0.43 |
| ▸ | AKT1 | P31749 | 11/20 | 0.42 |
| ▸ | KIT | P10721 | 2/20 | 0.37 |
| ▸ | AKT3 | Q9Y243 | 4/20 | 0.36 |
| ▸ | AKT2 | P31751 | 3/20 | 0.36 |
| ▸ | JAK1 | P23458 | 2/20 | 0.36 |
| ▸ | JAK2 | O60674 | 1/20 | 0.36 |
| ▸ | JAK3 | P52333 | 1/20 | 0.36 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.35 |
| ▸ | IL2 | P60568 | 2/20 | 0.34 |
| ▸ | TACR3 | P29371 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3724343 | 1.00 | MAP4K1 (0.43) | MAP4K1AKT1KITAKT3AKT2 | |
| SCHEMBL3723656 | 0.91 | MAP4K1 (0.45) | MAP4K1AKT1KITAKT3AKT2 | |
| SCHEMBL3722089 | 0.90 | AKT1 (0.41) | AKT1KITAKT3AKT2JAK1 | |
| SCHEMBL3722091 | 0.90 | AKT1 (0.41) | AKT1KITAKT3AKT2JAK1 | |
| SCHEMBL3720662 | 0.90 | AKT1 (0.44) | AKT1KITAKT3AKT2JAK1 | |
| SCHEMBL3720660 | 0.90 | AKT1 (0.44) | AKT1KITAKT3AKT2JAK1 | |
| SCHEMBL3730492 | 0.89 | AKT1 (0.45) | AKT1AKT3AKT2JAK1 | |
| SCHEMBL3730489 | 0.89 | AKT1 (0.45) | AKT1AKT3AKT2JAK1 | |
| SCHEMBL3725411 | 0.89 | AKT1 (0.42) | AKT1KITAKT3AKT2JAK1 | |
| SCHEMBL3725412 | 0.89 | AKT1 (0.42) | AKT1KITAKT3AKT2JAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8841304-B2 | Pyrrolopyridines as kinase inhibitors | ARRAY BIOPHARMA, INC. (US) | 2014-09-23 | — | — | US | disclosed |
| US-20140221370-A1 | PYRROLOPYRIDINES AS KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2014-08-07 | — | — | US | disclosed |
| EP-2242755-B1 | PYRROLOPYRIDINES AS KINASE INHIBITORS | ARRAY BIOPHARMA INC (US) | 2012-09-12 | — | — | EP | disclosed |
| US-20100324041-A1 | PYRROLOPYRIDINES AS KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2010-12-23 | — | — | US | disclosed |
| EP-2242755-A1 | PYRROLOPYRIDINES AS KINASE INHIBITORS | Array Biopharma, Inc. (US) | 2010-10-27 | — | — | EP | disclosed |
| WO-2009089352-A1 | PYRROLOPYRIDINES AS KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2009-07-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140221370-A1 | PYRROLOPYRIDINES AS KINASE INHIBITORS | CHEK2, CHEK1, BUB1B | MAP4K1 75/4885AKT1 537/4885KIT 1127/4885 |
| US-20100324041-A1 | PYRROLOPYRIDINES AS KINASE INHIBITORS | CHEK2, CHEK1, BUB1B | MAP4K1 65/4885AKT1 531/4885KIT 1158/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.